News for ATBPF Stock

Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma Antibe Reports Q3 2024 Interim Financial and Operating Results Antibe Extends Early Warrant Exercise Incentive Program Antibe Announces Early Warrant Exercise Incentive Program Antibe Therapeutics Announces Amendment to Warrant Terms Antibe Reports Q2 2024 Interim Financial and Operating Results Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul Antibe Announces Results of 2023 Annual Meeting Antibe Reports Q1 2024 Interim Financial and Operating Results Antibe Reports 2023 Year-End Results and Business Highlights Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference Antibe Provides April 2023 Corporate Update Antibe Reports Q3 2023 Interim Financial and Operating Results Antibe Reports Q2 2023 Interim Financial and Operating Results Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary Antibe Provides Development Update for Otenaproxesul Antibe Announces Results of 2022 Annual Meeting Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022 Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights Antibe Therapeutics Announces Amendment to Warrant Terms Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results Antibe Therapeutics Reports Q2 2022 Interim Financial and Operating Results Antibe Therapeutics Outlines Plan for Otenaproxesul';s Acute Pain Program Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Antibe Therapeutics Announces Results of 2021 Annual Meeting Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference Antibe Therapeutics Provides Clinical Update for Otenaproxesul Antibe Therapeutics Reports 2021 Year-End Financial Results and Business Highlights Antibe Therapeutics Collaborates With Dalriada Drug Discovery to Accelerate Pipeline Expansion Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain Antibe Therapeutics to Present at Upcoming Virtual Investor Conferences Antibe Therapeutics Reports Q3 2021 Interim Financial and Operating Results Antibe Therapeutics Announces Strategic Licensing Deal in China With Nuance Pharma Antibe Therapeutics Strengthens Partnering Advisory Team With Appointment of Don Haut Antibe Therapeutics Announces Intent to Unify Intellectual Property Ownership